MARKET

BCRX

BCRX

BioCryst Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.12
+0.20
+1.55%
After Hours: 13.12 0 0.00% 18:46 05/07 EDT
OPEN
12.69
PREV CLOSE
12.92
HIGH
13.19
LOW
12.52
VOLUME
6.45M
TURNOVER
--
52 WEEK HIGH
14.24
52 WEEK LOW
3.300
MARKET CAP
2.33B
P/E (TTM)
-12.0755
1D
5D
1M
3M
1Y
5Y
--Barclays Adjusts Price Target on BioCryst Pharmaceuticals to $20 From $13, Maintains Overweight Rating
MT Newswires · 12h ago
--RBC Boosts Price Target on BioCryst Pharmaceuticals to $11 From $9, Maintains Sector Perform, Speculative Risk
MT Newswires · 13h ago
72 Biggest Movers From Yesterday
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume.
Benzinga · 13h ago
Hereditary Angioedema Treatment Market Size, Share, Trends, Analysis and Forecast 2027
Market Insight Reports · 14h ago
Strength Seen in BioCryst (BCRX): Can Its 21% Jump Turn into More Strength?
Zacks.com · 16h ago
BioCryst shares surge 21% on Evercore upgrade, revenue beat
BioCryst Pharmaceuticals (BCRX) shares are up 21% after Evercore ISI upgraded the stock to outperform on strong Q1 results.Analyst Liisa Bayko also upped her price target on shares to $20 from $16.She
Seekingalpha · 1d ago
Why BioCryst Pharmaceuticals' Stock Is Trading Higher Today
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares are trading higher after the company reported better-than-expected Q1 sales results.
Benzinga · 1d ago
BioCryst (BCRX) Receives a Hold from Needham
Needham analyst Serge Belanger maintained a Hold rating on BioCryst (BCRX) today. The company's shares closed last Thursday at $12.52, close to its
SmarterAnalyst · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BCRX. Analyze the recent business situations of BioCryst Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BCRX stock price target is 16.22 with a high estimate of 20.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 260
Institutional Holdings: 128.94M
% Owned: 72.58%
Shares Outstanding: 177.65M
TypeInstitutionsShares
Increased
59
12.60M
New
38
6.82M
Decreased
55
22.50M
Sold Out
15
2.95M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Non-Executive Chairman/Independent Director
Robert Ingram
Chief Executive Officer/President/Director
Jon Stonehouse
Chief Financial Officer/Senior Vice President
Anthony Doyle
Senior Vice President/Secretary
Alane Barnes
Senior Vice President
Yarlagadda Babu
Senior Vice President
Charles Gayer
Senior Vice President
William Sheridan
Senior Vice President
Megan Sniecinski
Director
Sanj Patel
Chief Accounting Officer
Michael Jones
Vice President/General Manager
Allen Hodge
Other/Director
Helen Thackray
Independent Director
George Abercrombie
Independent Director
Stephen Aselage
Independent Director
Theresa Heggie
Independent Director
Nancy Hutson
Independent Director
Kenneth Lee
Independent Director
Alan Levin
No Data
  • All
  • Financials
  • Insiders
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Webull offers kinds of BioCryst Pharmaceuticals, Inc. stock information, including NASDAQ:BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.